Manipal Health Set for Flat Mumbai Debut After $960 Million IPO
THE SO WHAT
A $960M healthcare IPO pricing into a flat debut is another data point that public investors are tightening risk tolerance on non-AI growth stories. If you’re building in regulated services, assume a higher bar for public-market enthusiasm and keep private capital and strategic partnerships in your financing plan longer.
READ THE SOURCE
MORE FROM THE WIRE
Startups & VentureFintech startup Moss crowned Europe’s newest unicorn with €30m Series C
A €30m top-up to unicorn status says more about investor appetite for profitable, workflow-deep fintech than about round size. If you’re building in spend, credit, or treasury, assume the bar is now clear unit economics plus AI leverage, not just growth.
Startups & VentureAfter a decade of turning down VCs, Oxylabs hits $3.6bn valuation: 'Right timing, right partner'
A bootstrapped infra player reaching a $3.6bn valuation after a decade underscores how much value can accrue before touching venture capital. For founders in cash-generating niches, the playbook is shifting toward delaying dilution until you have clear leverage over terms and partner choice.
Startups & VentureWhat 144 new funds reveal about Europe's investment market
144 new funds in Europe means dry powder is not the constraint—fit to thesis and proof of AI-native defensibility are. Operators should treat this as a chance to be choosier on capital, not as a signal to chase valuation at the expense of runway and control.
Startups & VentureChina’s AI Agent Unicorn Lovart Is Said to Explore Hong Kong IPO
A Chinese AI design agent heading for a Hong Kong IPO is a marker that agentic verticals are maturing into standalone public-equity stories, not just features inside larger suites. For Western operators, assume Chinese agent players will have real capital and distribution in creative tools—differentiation will need to be workflow depth and ecosystem, not just model quality.